[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337153-105":59,"doc-detail-337153-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","serum-progastrin-releasing-peptide-in-pneumonia-chronic-obstructive-pulmonary-disease-and-early-stage-primary-lung-cancers","Serum progastrin-releasing peptide in pneumonia, chronic obstructive pulmonary disease and early-stage primary lung cancers","","Higher serum concentrations of pro-gastrin-releasing peptide (proGRP) in lung inflammation have been reported for small-cell lung cancer, but the overlap with other early primary lung cancers remained unclear. This observational study compared serum proGRP across pneumonia, COPD, and early-stage lung adenocarcinoma (ADC), squamous cell carcinoma (SQCC), and neuroendocrine tumors (NET), including SCLC. ProGRP was measured alongside established tumor markers and inflammatory markers, with statistical modeling using nonparametric tests and regression analyses. Results showed proGRP elevation in pneumonia, COPD, and NET versus early-stage ADC/SQCC, and associations with CRP and classification performance.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/serum-progastrin-releasing-peptide-in-pneumonia-chronic-obstructive-pulmonary-disease-and-early-stage-primary-lung-cancers/337153/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/serum-progastrin-releasing-peptide-in-pneumonia-chronic-obstructive-pulmonary-disease-and-early-stage-primary-lung-cancers/337153.png","ImageObject",300,407,{"name":92,"@type":93},"Genevieve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the main objective of the study?","Question",{"text":113,"@type":114},"To compare serum proGRP concentrations in pneumonia, COPD, and early-stage primary lung cancers, including ADC, SQCC, and NET.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How many cases were analyzed and which groups were included?",{"text":118,"@type":114},"The study analyzed 91 cases of pneumonia/COPD, 107 cases of early-stage lung ADC and SQCC, and 14 cases of NET including SCLC.",{"name":120,"@type":111,"acceptedAnswer":121},"What did the results show about proGRP levels across groups?",{"text":122,"@type":114},"ProGRP levels were higher in pneumonia, COPD, and NET compared with early-stage ADC and SQCC, and in some pneumonia/COPD cases proGRP reached an SCLC cut-off.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},337153,1790192921,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","| Highlights\u003Cbr>• In pneumonia and chronic obstructive pulmonary disease (COPD), median pro-gastrin-releasing peptide (proGRP) > 50 ng/L was measured\u003Cbr>• Median proGRP \u003C 40 ng/L was measured in the early-stage lung adenocarcinoma and squamous cell carcinoma\u003Cbr>• Pneumonia and COPD patients may have higher proGRP cut-offs compared to small-cell lung cancer\u003Cbr>• By using newly suggested rejection rules for the studied parameters, the analytical quality was not significantly improved |  |\n| --- | --- |\n| Abstract\u003Cbr>Introduction: Higher concentrations ofthe small-cell lung cancer (SCLC) serum marker, pro-gastrin-releasing peptide (proGRP), in lung inflammations has been indicated in literature. The objective of this study was to compare serum proGRP concentration in pneumonia, chronic obstructive pulmonary disease (COPD) and early-stage primary lung cancers.\u003Cbr>Materials and methods: An observational study was performed to assess serum proGRP against other lung cancer markers in pneumonia, COPD and in stage 1/2 carcinomas. A total of 91 cases of pneumonia or chronic obstructive pulmonary disease (COPD), with 107 cases of early-stage lung adenocarcinoma (ADC), squamous cell carcinoma (SQCC) and 14 cases of neuroendocrine tumors (NET), including SCLC, were analyzed. Serum proGRP (Roche Diagnostics, Basel, Switzerland), cytokeratin 19 fragment 21-1, carcinoembryonic antigen, neuron-specific enolase and C-reactive protein were measured and compared. For the statistical analysis, Mann-Whitney U test, Kruskal-Wallis ANOVA, multiple linear and multinomial logistic regression modeling were used.\u003Cbr>Results: Compared to the early-stage ADC and SQCC, proGRP in pneumonia, COPD and in NET was higher (P ≤ 0.011 in all comparisons). In 11 cases of pneumonia and COPD, proGRP reached cut-off for SCLC of 100 ng/L. No clinically relevant differences between pneumonia or COPD and early-stage cancer were observed for other markers. Concentration of proGRP was associated with CRP (model coefficient was 0.20; P \u003C 0.019) and both parameters contributed to classification of cases to pneumonia/COPD, ADC/SQCC, and NET categories (P \u003C 0.004, in all cases).\u003Cbr>Conclusions: Concentrations of proGRP in pneumonia and COPD patients were higher than in patients in the ADC and SQCC early stages and could exceed the SCLC cut-off.\u003Cbr>Keywords: pro-gastrin-releasing peptide; early-stage lung cancer; inflammation; serum tumor markers\u003Cbr>Submitted: March 27, 2024 Accepted: November 4, 2024 |  |\n| [https://doi.org/10.11613/BM.2025.010702](https://doi.org/10.11613/BM.2025.010702) | BiochemMed (Zagreb) 2025;35(1):010702 |\n\nOriginal article  \nSerum progastrin-releasing peptide in pneumonia, chronic obstructive pulmonary disease and early-stage primary lung cancers  \nGramos Begolli1, Maja Lukić2,3, Lada Rumora4, Lorna Čorak5, Andrea Vukić Dugac5,6, Marko Jakopović5,6, Miroslav Samaržija5,6, Ilijan Tomaš3,7, Jelena Knežević8,9, Željko Debeljak*2,3  \n1Clinic of Medical Biochemistry, University Clinical Center of Kosovo, Pristina, Kosovo  \n2Clinical Institute of Laboratory Diagnostics, University Hospital Centre Osijek, Osijek, Croatia  \n3Faculty of Medicine, JJ Strossmayer University of Osijek, Osijek, Croatia  \n4Department of Medical Biochemistry and Hematology, Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia  \n5University Hospital Center Zagreb, Zagreb, Croatia  \n6School of Medicine, University of Zagreb, Zagreb, Croatia  \n7Oncology Department, University Hospital Centre Osijek, Osijek, Croatia  \n8Laboratory for Advanced Genomics, Ruđer Bošković Institute, Zagreb, Croatia  \n9Faculty for Dental Medicine and Health, JJ Strossmayer University of Osijek, Osijek, Croatia  \n*[Corresponding author: zeljko.debeljak@gmail.com](Corresponding author: zeljko.debeljak@gmail.com)  \nSupplementary material available online for this article.  \n©Copyright by Croatian Society of Medical Biochemistry and Laboratory Medicine. This is an Open Access article distribu","cbCairB3FtREB5L4","https://ap.wps.com/l/cbCairB3FtREB5L4","pdf",173708,"English","# Introduction\n## Lung inflammation and diagnostic specificity of tumor markers\n## Lung cancer categories and limitations of existing markers\n# Materials and methods\n# Results\n# Conclusions","[{\"question\":\"What was the main objective of the study?\",\"answer\":\"To compare serum proGRP concentrations in pneumonia, COPD, and early-stage primary lung cancers, including ADC, SQCC, and NET.\"},{\"question\":\"How many cases were analyzed and which groups were included?\",\"answer\":\"The study analyzed 91 cases of pneumonia/COPD, 107 cases of early-stage lung ADC and SQCC, and 14 cases of NET including SCLC.\"},{\"question\":\"What did the results show about proGRP levels across groups?\",\"answer\":\"ProGRP levels were higher in pneumonia, COPD, and NET compared with early-stage ADC and SQCC, and in some pneumonia/COPD cases proGRP reached an SCLC cut-off.\"}]","Serum progastrin-releasing peptide in pneumonia, chronic obstructive pulmonary disease and early-stage primary lung cancers | PDF",1790017893,25,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/627311820cbd9bc32aa93e8828017262.webp",983,1366,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a388817316fdc2af2fb63e420060b372.webp",982,1365,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f09f5c90b8d841ec121b66f1c9baef0f.webp",981,1363,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c0337621f347296446cd1a48b6976aaa.webp",980,1362]